表紙
市場調查報告書

生物科技及醫藥品領域的奈米粒子的全球市場:2017年∼2021年

Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 582989
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
生物科技及醫藥品領域的奈米粒子的全球市場:2017年∼2021年 Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021
出版日期: 2017年11月20日內容資訊: 英文 88 Pages
簡介

關於奈米粒子

奈米粒子是由合成或半合成聚合物組成的亞奈米級膠體結構。這些技術被用於生物技術和製藥領域,用於研究疾病診斷的生物系統,並側重於分子水平的治療。許多常規材料的性質在奈米粒子形成時改變,原因是奈米粒子比每個重量大的顆粒具有更大的表面積,使得它們對其他分子更具反應性。

Technavio的分析師預測,從2017年到2021年期間,生物科技及醫藥品領域的奈米粒子的全球市場將以21.72%的年複合成長率成長。

本報告提供生物科技及醫藥品領域的奈米粒子的全球市場調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 市場情形

  • 市場規模與預測
  • 波特的五力分析

第6章 市場劃分:各終端用戶

  • 比較:各終端用戶
  • 生物科技
  • 醫藥品
  • 市場機會:各終端用戶

第7章 地區情形

  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第8章 決策架構

第9章 成長要素與課題

  • 市場成長要素
  • 市場課題

第10章 市場趨勢

  • 幹細胞療法的奈米粒子需求的增加
  • 慢性疾病的盛行率的增加
  • 黃金奈米粒子的使用增加

第11章 供應商情形

  • 競爭模式
  • 投資機會

第12章 供應商分析

  • 供應商概要
  • Merck
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Novartis
  • 其他有力供應商

第13章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR15521

About Nanoparticles

Nanoparticles are sub-nanosized colloidal structures composed of synthetic or semi-synthetic polymers. These are used in biotechnology and pharmaceutical sectors for studying biological systems for diagnosing diseases and focusing on treatment at the molecular level. The properties of many conventional materials alter when formed from nanoparticles, the reason being nanoparticles have a greater surface area per weight than larger particles, making them more reactive to other molecules

Technavio's analysts forecast the global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis

Other Prominent Vendors

  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB

Market driver

  • Rising R&D expenditure in pharmaceutical and biotechnology sectors
  • For a full, detailed list, view our report

Market challenge

  • Challenges in development of nanoparticles for therapeutics
  • For a full, detailed list, view our report

Market trend

  • Increasing demand for nanoparticles in stem cell therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market size and forecast
  • Five forces analysis

PART 06: MARKET SEGMENTATION BY END-USER

  • Comparison by end-user
  • Biotechnology
  • Pharmaceutical
  • Market opportunity by end-user

PART 07: REGIONAL LANDSCAPE

  • Regional comparison
  • Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
  • Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
  • Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
  • Market opportunity

PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

  • Increasing demand for nanoparticles in stem cell therapy
  • Increasing prevalence of chronic diseases
  • Increasing use of gold nanoparticles

PART 11: VENDOR LANDSCAPE

  • Competitive scenario
  • Investment opportunity

PART 12: VENDOR ANALYSIS

  • Vendor overview
  • Merck
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Novartis
  • Other prominent vendors

PART 13: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Applications of nanoparticles in biotechnology and pharmaceutical sectors
  • Exhibit 02: Detection of cancer cells in bloodstream through use of nanoparticles
  • Exhibit 03: Global nanoparticles market in biotechnology and pharmaceutical sectors: Market overview
  • Exhibit 04: Global nanoparticles market in biotechnology and pharmaceutical sectors 2016-2021 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global nanoparticles market in biotechnology and pharmaceutical sectors by end-user 2016-2021 (% share)
  • Exhibit 07: Comparison by end-user
  • Exhibit 08: Global nanoparticles market by biotechnology 2016-2021 ($ billions)
  • Exhibit 09: Global nanoparticles market by biotechnology - Year over year growth
  • Exhibit 10: Global nanoparticles market by pharmaceutical 2016-2021 ($ billions)
  • Exhibit 11: Nanoparticles in pharmaceuticals
  • Exhibit 12: Global nanoparticles market by pharmaceutical - Year over year growth
  • Exhibit 13: Global nanoparticles market in biotechnology and pharmaceutical sectors by region 2016-2021 (% share)
  • Exhibit 14: Regional comparison
  • Exhibit 15: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas 2016-2021 ($ billions)
  • Exhibit 16: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas - Year over year growth
  • Exhibit 17: Top 3 countries in Americas
  • Exhibit 18: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA 2016-2021 ($ billions)
  • Exhibit 19: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA - Year over year growth
  • Exhibit 20: Top 3 countries in EMEA
  • Exhibit 21: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC 2016-2021 ($ billions)
  • Exhibit 22: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC - Year over year growth
  • Exhibit 23: Top 3 countries in APAC
  • Exhibit 24: Nanoparticle-based products under clinical trials
  • Exhibit 25: Major chronic disease-related deaths 2012 (in thousands)
  • Exhibit 26: Strategic success factors for vendors to consider
  • Exhibit 27: Investment opportunity mapping
  • Exhibit 28: Merck: Profile
  • Exhibit 29: Merck: Strength analysis
  • Exhibit 30: Merck: Strategy assessment
  • Exhibit 31: Merck: Opportunity assessment
  • Exhibit 32: F. Hoffmann-La Roche: Profile
  • Exhibit 33: F. Hoffmann-La Roche: Strength analysis
  • Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 36: GE Healthcare: Profile
  • Exhibit 37: GE Healthcare: Strength analysis
  • Exhibit 38: GE Healthcare: Strategy assessment
  • Exhibit 39: GE Healthcare: Opportunity assessment
  • Exhibit 40: Novartis: Profile
  • Exhibit 41: Novartis: Strength analysis
  • Exhibit 42: Novartis: Strategy assessment
  • Exhibit 43: Novartis: Opportunity assessment
Back to Top